Skip to main content

14-08-2018 | Lupus nephritis | Review | Article

Induction Therapy for Lupus Nephritis: the Highlights

Current Rheumatology Reports

Authors: Isabelle Ayoub, Jessica Nelson, Brad H. Rovin

Publisher: Springer US


Purpose of Review

Lupus nephritis is a frequent complication of systemic lupus erythematosus and is more common and severe in children. This is a disease of the immune system characterized by T cell, B cell, and complement activation, as well as immune complex formation and deposition. The introduction of steroids and later cyclophosphamide transformed lupus nephritis from a fatal to a treatable condition. However, the standard therapies currently used for treatment carry significant toxicity and chronic kidney disease still remains a far too frequent outcome. To address these issues, we will review current and emerging induction therapies in LN.

Recent Findings

Several clinical trials have been undertaken to test more effective and safer drugs, often targeting mechanistic disease pathways.


At present, it is difficult to identify an induction regimen that is more effective and less toxic than the standard of care; however, we believe continuing efforts in drug development will bring breakthrough agents to clinics.

Please log in to get access to this content

Related topics

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits